SAFETY AND EFFICACY OF THREE TREATMENT REGIMENS OF R-CHOP, E-CHOP, AND R-CHOEP IN NON-HODGKIN LYMPHOMA CANCER PATIENTS

Ayaz Ahmad; Mohammad Daud Ali; Sana Almahmoud

doi:10.22159/ajpcr.2018.v11i6.24345

Authors

Ayaz Ahmad Department of Pharmacy, Mohammad Almana College of Health Sciences, Abdulrazaq Bin Hammam Street, As Safa, Dammam 34222, Saudi Arabia.
Mohammad Daud Ali Department of Pharmacy, Mohammad Almana College of Health Sciences, Abdulrazaq Bin Hammam Street, As Safa, Dammam 34222, Saudi Arabia.
Sana Almahmoud Department of Nursing Education, College of Nursing, Imam Abdulrahman Bin Faisal University, King Faisal Road, Dammam 34212, Saudi Arabia.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i6.24345

Keywords:

Non-hodgkin lymphoma, Eastern Cooperative Oncology Group score, Prognostic index, Response evaluation criteria in solid tumors criteria

Abstract

Objective: This study was designed to investigate safety, efficacy of different regimens such as R-CHOP, E-CHOP, and R-CHOEP used in the treatment of in non-Hodgkin lymphoma (NHL) cancer patients.

Methods: Available and required data of 64 NHL cancer patients were collected. Data were related to demography of patients, name of the drug, dose, route, frequency, duration of therapy, and investigational reports.

Results: This study showed some variation and similarities in different regimens. Arm-A (R-CHOP) and Arm-B (E-CHOP) showed similar result for Eastern Cooperative Oncology Group (ECOG) score 2 but showed different result of ECOG score 0 and 1. High percentage of patient was taken in Arm-A and Arm-B as compared to Arm-C (R-CHOEP) for ECOG score 2. Surprisingly, it was found that very few percentages of patients showing progressive disease during R-CHOEP as compared to R-CHOP, E-CHOP therapy.

Conclusion: From this study, it was concluded that Arm-C (R-CHOEP) showed better result in comparison of Arm-A (R-CHOP) and Arm-B (E-CHOP). As far as toxicity is concern, early detection and personalized management may improve clinical outcome and tolerance.

Downloads

Download data is not yet available.

Author Biography

Ayaz Ahmad, Department of Pharmacy, Mohammad Almana College of Health Sciences, Abdulrazaq Bin Hammam Street, As Safa, Dammam 34222, Saudi Arabia.

Associate professor

Department of pahrmacology

School of Pharmacy

Mohammed almana college of health sciences

Abdulrazaq Bin Hammam Street, As Safa, Dammam 34222

References

Elizabeth JT. Dorlandâ€™s Illustrated Medical Dictionary. 29th ed. Philadelphia, PA: Saunders; 2000. p. 1038.

National Cancer Institute. General Information About Adult Hodgkin Lymphoma. Bethesda, MD: National Cancer Institute; 2014.

National Cancer Institute. General Information about Adult non- Hodgkin Lymphoma. Bethesda, MD: National Cancer Institute; 2014. Available from: https://www.cancer.gov/types/lymphoma/patient/ adult-nhl-treatment-pdq. [Last retrieved on 2014 Jun20].

Bardia A. Johns Hopkins Patientsâ€™ Guide to Lymphoma. Burlington, Massachusetts, United States: Jones and Bartlett Learning; 2010. p. 6.

Available from: https://www.lls.org/sites/default/files/file_assets/ lymphomaguide.pdf.

Available from: http://www.publications.iarc.fr/Non-Series-Publications/ World-Cancer-Reports/World-Cancer-Report-2014.

Hande KR. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;34:1514-21.

Antony A, Joel JJ, Shetty J, Umar NF. Identification and analysis of adverse drug reactions associated with cancer chemotherapy in hospitalized patients. Int J Pharm Pharm Sci 2016;8:448-51.

Yang L, Dong J, Jiang S, Shi W, Xu X, Huang H, et al. Red and processed meat consumption increases risk for non-hodgkin lymphoma: A PRISMA-compliant meta-analysis of observational studies. Medicine (Baltimore) 2015;94:e1729.

Solimini AG, Lombardi AM, Palazzo C, De Giusti M. Meat intake and non-hodgkin lymphoma: A meta-analysis of observational studies. Cancer Causes Control 2016;27:595-606.

Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, et al. Spectrum of epstein-barr virus-related diseases: A pictorial review. Jpn J Radiol 2009;27:4-19.

Available from: https://www.seer.cancer.gov/statfacts/html/nhl.html.

Etoposideâ€. The American Society of Health-System Pharmacists. Available from: http://www.bccancer.bc.ca/drug-database-site/ Drug%20Index/Etoposide_monograph_1Mar2017.pdf. [Last retrieved on 2016 Dec 08].

Gupta M, Dahiya J, Marwaha RK, Dureja H.Therapies in Cancer Treatment: An Overview. Int J Pharm Pharm Sci 2015;7:1-9.

Bosch X, Ramos C, Manuel K, Munther A. Drugs Targeting B-Cells in Autoimmune Diseases. Berlin/Heidelberg, Germany: Springer Science & Business Media; 2013. p. 1-4.

WHO. WHO Model Formulary 2008. Geneva: World Health Organization; 2009. p. 227. Available from: http://apps.who.int/iris/ handle/10665/44053. [Last retrieved on 2016 Dec 08].

Bosch X, Ramos C, Manuel K, Munther A. Drugs Targeting B-Cells in Autoimmune Diseases. Berlin/Heidelberg, Germany: Springer Science & Business Media; 2013. p. 1-4.

WHO. Model List of Essential Medicines. 19th List. Geneva: World Health Organization; 2015. Available from: http://www.who.int/ medicines/publications/essentialmedicines/en/. [Last retrieved on 2016 Dec 08].

Saini KS, Azim HA Jr., Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, et al. Rituximab in Hodgkin lymphoma: Is the target always a hit? Cancer Treat Rev 2011;37:385-90.s